Tobias Schupp1,2, Michael Behnes3,4, Christel Weiß5, Christoph Nienaber6, Siegfried Lang1,2, Linda Reiser1,2, Armin Bollow1,2, Gabriel Taton1,2, Thomas Reichelt1,2, Dominik Ellguth1,2, Niko Engelke1,2, Uzair Ansari1,2, Ibrahim El-Battrawy1,2, Thomas Bertsch7, Muharrem Akin8, Kambis Mashayekhi9, Martin Borggrefe1,2, Ibrahim Akin1,2. 1. First Department of Medicine, University Medical Center Mannheim (UMM) Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany. 2. European Center for AngioScience (ECAS) and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany., Mannheim, Germany. 3. First Department of Medicine, University Medical Center Mannheim (UMM) Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany. michael.behnes@umm.de. 4. European Center for AngioScience (ECAS) and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany., Mannheim, Germany. michael.behnes@umm.de. 5. Institute of Biomathematics and Medical Statistics, Faculty of Medicine Mannheim, University Medical Center Mannheim (UMM), Heidelberg University, Mannheim, Germany. 6. Royal Brompton and Harefield Hospitals, NHS, London, UK. 7. Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany. 8. Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. 9. Division of Cardiology and Angiology II, University Heart Centre Freiburg Bad Krozingen, University of Freiburg, Bad Krozingen, Germany.
Abstract
OBJECTIVE: The study sought to assess the impact of treatment with beta-blocker (BB) or ACE inhibitor/angiotensin receptor blocker (ACEi/ARB) on secondary survival in patients presenting with ventricular tachyarrhythmia. BACKGROUND: Data regarding outcome of patients presenting with ventricular tachyarrhythmia treated with BB and ACEi/ARB is limited. METHODS: A large retrospective registry was used including consecutive patients presenting with ventricular tachycardia and fibrillation from 2002 to 2016 on admission. Applying propensity-score matching for harmonization, the impact of "BB" and "ACEi/ARB" was comparatively evaluated. The primary prognostic outcome was long-term all-cause death at 3 years. RESULTS: A total of 972 matched patients were included. Both patients with BB (long-term mortality rate 18 versus 27%; log rank p = 0.041; HR = 0.661; 95% CI = 0.443-0.986; p = 0.043) and with ACEi/ARB (long-term mortality rate 13 versus 23%; log rank p = 0.004; HR = 0.544; 95% CI = 0.359-0.824; p = 0.004) revealed better secondary survival compared to patients without after presenting with ventricular tachyarrhythmia on admission. The prognostic benefit of BB was comparable to ACEi/ARB (long-term mortality rate 21 versus 26%; log rank p = 0.539). CONCLUSION: BB and ACEi/ARB were associated with improved secondary survival in patients surviving ventricular tachyarrhythmia on admission. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02982473.
OBJECTIVE: The study sought to assess the impact of treatment with beta-blocker (BB) or ACE inhibitor/angiotensin receptor blocker (ACEi/ARB) on secondary survival in patients presenting with ventricular tachyarrhythmia. BACKGROUND: Data regarding outcome of patients presenting with ventricular tachyarrhythmia treated with BB and ACEi/ARB is limited. METHODS: A large retrospective registry was used including consecutive patients presenting with ventricular tachycardia and fibrillation from 2002 to 2016 on admission. Applying propensity-score matching for harmonization, the impact of "BB" and "ACEi/ARB" was comparatively evaluated. The primary prognostic outcome was long-term all-cause death at 3 years. RESULTS: A total of 972 matched patients were included. Both patients with BB (long-term mortality rate 18 versus 27%; log rank p = 0.041; HR = 0.661; 95% CI = 0.443-0.986; p = 0.043) and with ACEi/ARB (long-term mortality rate 13 versus 23%; log rank p = 0.004; HR = 0.544; 95% CI = 0.359-0.824; p = 0.004) revealed better secondary survival compared to patients without after presenting with ventricular tachyarrhythmia on admission. The prognostic benefit of BB was comparable to ACEi/ARB (long-term mortality rate 21 versus 26%; log rank p = 0.539). CONCLUSION: BB and ACEi/ARB were associated with improved secondary survival in patients surviving ventricular tachyarrhythmia on admission. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02982473.
Authors: Ibrahim Akin; Michael Behnes; Julian Müller; Jan Forner; Mohammad Abumayyaleh; Kambis Mashayekhi; Muharrem Akin; Thomas Bertsch; Kathrin Weidner; Jonas Rusnak; Dirk Große Meininghaus; Maximilian Kittel; Tobias Schupp Journal: J Clin Med Date: 2022-05-25 Impact factor: 4.964
Authors: Tobias Schupp; Max von Zworowsky; Linda Reiser; Mohammad Abumayyaleh; Kathrin Weidner; Kambis Mashayekhi; Thomas Bertsch; Mohammed L Abba; Ibrahim Akin; Michael Behnes Journal: Pharmacology Date: 2021-12-08 Impact factor: 2.547
Authors: Elizabeth Davida Paratz; Luke Rowsell; Dominica Zentner; Sarah Parsons; Natalie Morgan; Tina Thompson; Paul James; Andreas Pflaumer; Christopher Semsarian; Karen Smith; Dion Stub; Andre La Gerche Journal: Open Heart Date: 2020-01-20
Authors: Tobias Schupp; Michael Behnes; Mohammad Abumayyaleh; Kathrin Weidner; Kambis Mashayekhi; Thomas Bertsch; Ibrahim Akin Journal: J Clin Med Date: 2022-03-07 Impact factor: 4.241
Authors: Tobias Schupp; Michael Behnes; Mohammad Abumayyaleh; Kathrin Weidner; Jonas Rusnak; Kambis Mashayekhi; Thomas Bertsch; Ibrahim Akin Journal: J Cardiovasc Dev Dis Date: 2022-08-16